A61K 31/416 (20130101)
The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like.
Klein, Thomas W.; Newton, Catherine; Patterson, Cahterine; and Agudelo, Marisela, "Methods and compositions for reducing serum levels of immunoglobulin E (IgE)" (2016). USF Patents. 842.
University of South Florida